Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular autonomic neuropathy: Diagnosis and management

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Cardiovascular autonomic neuropathy increases morbidity and mortality, and reduces quality of life and activities of daily living of the patients with diabetes. The reduced cardiovascular autonomic function as measured by heart rate variability is strongly associated with an increased risk of silent myocardial ischemia and mortality. Currently, no specific therapeutic strategies can be recommended for cardiac autonomic neuropathy, but management of hyperglycemia and the use of angiotensin-converting enzyme inhibitors and β blockers should be instituted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Low PA, Benrud-Larson LM, Sletten DM, et al.: Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004, 27:2942–2947. Important demonstration of the frequency of symptoms that do not relate to quantitative autonomic function tests.

    Article  PubMed  Google Scholar 

  2. Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553–1579. An excellent review of features of autonomic neuropathy and the basis of the American Diabetes Association guidelines for diagnosis and management autonomic neuropathy.

    Article  PubMed  Google Scholar 

  3. Ziegler D: Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Rev 1999, 7:342–357.

    Google Scholar 

  4. Neil HA, Thompson AV, John S, et al.: Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically de.ned population. Diabet Med 1989, 6:20–24.

    PubMed  CAS  Google Scholar 

  5. Ziegler D, Gries FA, Spuler M, Lessmann F: The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992, 6:49–57.

    Article  PubMed  CAS  Google Scholar 

  6. O’Brien IA, O’Hare JP, Lewin IG, Corrall RJ: The prevalence of autonomic neuropathy in insulin-dependent diabetes: a controlled study based on heart rate variability. Q J Med 1986, 61:957–967.

    PubMed  CAS  Google Scholar 

  7. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trail (DCCT). Diabetes Control and Complications Trial Research Group [no authors listed]. Diabetologia 1998, 41:416-423.

  8. Valensi P, Paries J, Attali JR: Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications—the French multicenter study. French Group for Research and Study of Diabetic Neuropathy. Metabolism 2003, 52:815–820.

    Article  PubMed  CAS  Google Scholar 

  9. Witte DR, Tesfaye S, Chaturvedi N, et al.: Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005, 48:164–171.

    Article  PubMed  CAS  Google Scholar 

  10. Vinik AI, Erbas T: Neuropathy. In Handbook of Exercise in Diabetes. Edited by Ruderman N, et al.: Alexandria, VA: American Diabetes Association; 2002:463–496.

    Google Scholar 

  11. Vinik AI, Erbas T: Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001, 68:928–944.

    Article  PubMed  CAS  Google Scholar 

  12. Taskiran M, Rasmussen V, Rasmussen B, et al.: Left ventricular dysfunction in normotensive type 1 diabetic patients: the impact of autonomic neuropathy. Diabet Med 2004, 21:524–530.

    Article  PubMed  CAS  Google Scholar 

  13. Burgos LG, Ebert TJ, Asiddao C, et al.: Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989, 70:591–597.

    Article  PubMed  CAS  Google Scholar 

  14. Kitamura A, Hoshino T, Kon T, et al.: Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature. Anesthesiology 2000, 92:1311–1318.

    Article  PubMed  CAS  Google Scholar 

  15. Sobotka PA, Liss HP, Vinik AI: Impaired hypoxic ventilatory drive in diabetic patients with autonomic neuropathy. J Clin Endocrinol Metab 1986, 62:658–663.

    PubMed  CAS  Google Scholar 

  16. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes Group [no authors listed]. Am J Cardiol 1997, 79:134-139.

  17. Lee K, Jang H, Kim Y, et al.: Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. Am J Cardiol 2003, 92:1458–1461.

    Article  PubMed  Google Scholar 

  18. Valensi P, Sachs RN, Harfouche B, et al.: Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001, 24:339–343.

    Article  PubMed  CAS  Google Scholar 

  19. Wackers FJ, Young LH, Inzucchi SE, et al.: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Detection of Ischemia in Asymptomatic Diabetics Investigators. Diabetes Care 2004, 27:1954–1961.

    Article  PubMed  Google Scholar 

  20. Carli MF, Bianco-Batlles D, Landa ME, et al.: Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999, 100:813–819.

    PubMed  Google Scholar 

  21. Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group [no authors listed]. Eur Heart J 1992, 13:594-598.

  22. Aronson D, Weinrauch LA, D’Elia JA, et al.: Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Am J Cardiol 1999, 84:449–453.

    Article  PubMed  CAS  Google Scholar 

  23. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21:69–75.

    Article  PubMed  CAS  Google Scholar 

  24. Katz A, Liberty IF, Porath A, et al.: A simple beside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J 1999, 138:32–38.

    Article  PubMed  CAS  Google Scholar 

  25. Hume L, Oakley GD, Boulton AJ, et al.: Asymptomatic myocardial ischemia in diabetes and its relationship to diabetic neuropathy: an exercise electrocardiography study in middle-aged diabetic men. Diabetes Care 1986, 9:384–388.

    Article  PubMed  CAS  Google Scholar 

  26. Astrup AS, Tarnow L, Rossing P, et al.: Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29:334–339.

    Article  PubMed  Google Scholar 

  27. Ewing DJ, Boland O, Neilson JM, et al.: Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991, 34:182–185.

    Article  PubMed  CAS  Google Scholar 

  28. Rathmann W, Ziegler D, Jahnke M, et al.: Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993, 10:820–824.

    PubMed  CAS  Google Scholar 

  29. O’Brian IA, McFadden JP, Corrall R: The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991, 79:495–502.

    Google Scholar 

  30. Gerritsen J, Dekker JM, TenVoorde BJ, et al.: Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 2001, 24:1793–1798.

    Article  PubMed  CAS  Google Scholar 

  31. Veglio M, Borra M, Stevens LK, et al.: The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complications Study Group. Diabetologia 1999, 42:68–75.

    Article  PubMed  CAS  Google Scholar 

  32. Suarez GA, Clark VM, Norell JE, et al.: Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry 2005, 76:240–245.

    Article  PubMed  CAS  Google Scholar 

  33. Vinik AI, Freeman R, Erbas T: Diabetic autonomic neuropathy. Semin Neurol 2003, 23:365–372.

    Article  PubMed  Google Scholar 

  34. Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement [no authors listed]. Diabetes 1988, 37:1000-1004.

  35. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. American Diabetes Association and American Academy of Neurology [no authors listed]. Diabetes Care 1992, 15:1080-1107.

  36. Freeman R, Saul P, Roberts M, et al.: Spectral analysis of heart rate in diabetic autonomic neuropathy. Arch Neurol 1991, 48:185–190.

    PubMed  CAS  Google Scholar 

  37. Risk M, Bril V, Broadbridge C, Cohen A: Heart rate variability measurement in diabetic neuropathy: review of methods. Diabetes Technol Ther 2001, 3:63–76.

    Article  PubMed  CAS  Google Scholar 

  38. Schumer MP, Joyner SA, Pfeifer MA: Cardiovascular autonomic neuropathy testing in patients with diabetes. Diabetes Spectrum 1998, 11:227–231.

    Google Scholar 

  39. Ziegler D, Laux G, Dannehl K, et al.: Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 1992, 9:166–175.

    Article  PubMed  CAS  Google Scholar 

  40. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology [no authors listed]. Circulation 1996, 93:1043-1065.

    Google Scholar 

  41. Tutuncu NB, Batur MK, Yildirir A, et al.: Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res 2005, 39:43–49.

    Article  PubMed  CAS  Google Scholar 

  42. Bigger JT Jr, Fleiss JL, Steinman RC, et al.: Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992, 85:164–171.

    PubMed  Google Scholar 

  43. Fava S, Azzopardi J, Muscat HA, et al.: Factors that in.uence outcome in diabetic subjects with myocardial infarction. Diabetes Care 1993, 16:1615–1618.

    Article  PubMed  CAS  Google Scholar 

  44. Nishimura M, Hashimoto T, Kobayashi H, et al.: Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrol Dial Transplant 2004, 19:2532–2538.

    Article  PubMed  Google Scholar 

  45. Gonin JM, Kadrofske MM, Schmaltz S, et al.: Corrected Q-T interval prolongation as diagnostic tool for assessment of cardiac autonomic neuropathy in diabetes mellitus. Diabetes Care 1990, 13:68–71.

    Article  PubMed  CAS  Google Scholar 

  46. Sawicki PT, Kiwitt S, Bender R, et al.: The value of QT interval dispersion for identi.cation of total mortality risk in non-insulin-dependent diabetes mellitus. J Intern Med 1998, 243:49–56.

    Article  PubMed  CAS  Google Scholar 

  47. Howorka K, Pumprla J, Haber P, et al.: Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res 1997, 34:206–214.

    Article  PubMed  CAS  Google Scholar 

  48. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group [no authors listed]. Ann Intern Med 1995, 122:561-568.

  49. Burger AJ, Weinrauch LA, D’Elia JA, Aronson D: Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 1999, 84:687–691.

    Article  PubMed  CAS  Google Scholar 

  50. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999, 353:617–622.

    Article  PubMed  CAS  Google Scholar 

  51. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103–117.

    Article  PubMed  CAS  Google Scholar 

  52. Kontopoulos AG, Athyros VG, Didangelos TP, et al.: Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997, 20:355–361.

    Article  PubMed  CAS  Google Scholar 

  53. Malik RA, Williamson S, Abbott C, et al.: Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998, 352:1978–1981.

    Article  PubMed  CAS  Google Scholar 

  54. Ebbehoj E, Poulsen PL, Hansen KW, et al.: Effects on heart rate variability of metoprolol supplementary to on going ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 2002, 45:965–975.

    Article  PubMed  CAS  Google Scholar 

  55. Ziegler D, Reljanovic M, Mehnert H, Gries FA: Alphalipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999, 107:421–430.

    Article  PubMed  CAS  Google Scholar 

  56. Manzella D, Barbieri M, Ragno E, Paolisso G: Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 2001, 73:1052–1057.

    PubMed  CAS  Google Scholar 

  57. Maser RE, Mitchell BD, Vinik AI, Freeman R: The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003, 26:1895–1901. A meta-analysis that establishes the link between irrefutably autonomic neuropathy and premature demise.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, 855 W. Brambleton Avenue, 23510, Norfolk, VA, USA

    Aaron I. Vinik MD, PhD

Authors
  1. Aaron I. Vinik MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomris Erbas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron I. Vinik MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vinik, A.I., Erbas, T. Cardiovascular autonomic neuropathy: Diagnosis and management. Curr Diab Rep 6, 424–430 (2006). https://doi.org/10.1007/s11892-006-0074-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-006-0074-z

Keywords

Search

Navigation